Drug firm Lupin on Tuesday said it has launched generic Zileuton extended-release tablets - used for the treatment of asthma - in the US market. The product is a generic version of Chiesi USA Inc's Zyflo CR extended-release tablets in the same strength, it added. The company has launched Zileuton extended-release tablets in the strength of 600 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a BSE filing. According to IQVIA MAT June 2020 data, Zileuton extended-release tablets had an annual sales of approximately USD 40 million in the US, Lupinsaid. The tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older, it added. Shares of Lupin Ltd closed at Rs957.95per scrip on the BSE, up 0.01 per cent from its previous close.
Asthma does not appear to increase the risk for a person contracting Covid-19 or affect its severity, according to a new research
There's been a run on inhalers, and coronavirus patients like the actor Idris Elba have openly worried about their asthma.
The Center at Coral Springs, Florida, focuses on research and development of respiratory products for the treatment of asthma, chronic obstructive pulmonary diseases and other respiratory ailments.
The medicine is indicated for prophylaxis and treatment of chronic asthma in adults and children 12 years of age and older, it added.
A mice treated with "zileuton" experienced a 90% reduction in the formation of leukotrienes
New research furthers understanding of the role microscopic organisms play in overall health
Among those who have a week-long sleeping disorder, the risk increases by 94%
Researchers ruled out asthma in 203 people, most of whom were taking asthma medicine.
Some 13.5 per cent of children had asthma when they enrolled in the study
Cured and processed meat is rich in nitrites, which may have a role in airway inflammation
Risk of allergic diseases increases with the number of food allergies a child might have, say researchers